<DOC>
	<DOCNO>NCT00310492</DOCNO>
	<brief_summary>This trial perform assess efficacy safety ALK-depot SQ mites treatment atopic dermatitis</brief_summary>
	<brief_title>Efficacy Safety Trial ALK-depot SQ Mites Subjects With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Positive specific IgE house dust mites Atopic dermatitis accord Hanifin/Rajka Chronic course Atopic dermatitis SCORAD large 25 point Erythrodermia Syst.treatment gc immunosuppressive agent prev.4 week History specific immunotherapy mite UV radiation Group 4 topical corticosteroid ( European classification )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>